TC-1698
Legal status
Legal status
  • In general: legal
Identifiers
  • 2-pyridin-3-yl-1-azabicyclo[3.2.2]nonane
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18N2
Molar mass202.301 g·mol−1
3D model (JSmol)
  • c2ncccc2C1CCC3CCN1CC3
  • InChI=1S/C13H18N2/c1-2-12(10-14-7-1)13-4-3-11-5-8-15(13)9-6-11/h1-2,7,10-11,13H,3-6,8-9H2 ☒N
  • Key:WIEWCOLOPGXZDJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

TC-1698 is a drug developed by Targacept which acts as a partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1] It has neuroprotective effects in animal studies,[2] and has been used as a lead compound to find further potent derivatives.[3]

See also

References

  1. ↑ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  2. ↑ Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M (April 2004). "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 16–27. CiteSeerX 10.1.1.420.2457. doi:10.1124/jpet.103.061655. PMID 14722323. S2CID 7730290.
  3. ↑ Bhatti BS, Strachan JP, Breining SR, Miller CH, Tahiri P, Crooks PA, et al. (May 2008). "Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands". The Journal of Organic Chemistry. 73 (9): 3497–507. doi:10.1021/jo800028q. PMID 18363376.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.